Thermo Fisher Scientific announces license agreement to develop, commercialize deep learning tools for proteomics

Thermo Fisher Scientific, the world leader in serving science, and MSAID GmbH, a software company transforming proteomics with deep learning, announce an exclusive license agreement to develop and commercialize deep learning tools for proteomics, making MSAID’s Prosit-derived framework widely accessible to proteomics laboratories. The availability of deep learning tools will enable improved confidence in proteomics research results, primarily in the areas of protein profiling using label-free or tandem mass tag (TMT)-based quantification, and a variety of new applications.

The new algorithm allows gains in confidence and reproducibility and will be released as part of Thermo Fisher’s newest Thermo Scientific Proteome Discoverer 2.5 software release. Users can now access deep-learning-based prediction of tandem mass spectra, allowing for the formation of entire spectral libraries on demand and facilitating the identification of peptides with up to 10 times higher confidence and the extraction of more identifications from proteomics datasets via intensity-based rescoring. In combination with Thermo Scientific Orbitrap technology, the new algorithm enables emerging applications, such as immunopeptidomics and metaproteomics, for which traditional database search and statistical approaches are often ineffective.

Increasing the confidence of protein and peptide identifications is a growing need, given that a false discovery rate of even 1% means that 1,000 out of every 100,000 peptides might be incorrectly assigned. Applying deep learning tools enables data-independent analysis of proteomics samples with higher confidence and reproducibility, and, when used with Orbitrap technology, reduces the false discovery rate 10-fold, to merely 100 out of every 100,000 peptides."

Mark Sanders, Director of life science mass spectrometry software, Thermo Fisher Scientific

At MSAID, we reinvent the way proteomic data is acquired and analyzed by using state-of-the-art deep learning. Through our collaboration with Thermo Fisher Scientific, we can bring this technological revolution to laboratories around the world and empower the scientific community to gain exceptional insight into new and existing data."

Martin Frejno, Chief executive officer, MSAID GmbH

Thermo Fisher Scientific will showcase outcomes of the collaboration and its newest products and software solutions in a company-hosted virtual event, vLC-MS.com, from May 26-28, 2020, and at the American Society for Mass Spectrometry (ASMS) Reboot Program, from June 1-12, 2020.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2020, May 28). Thermo Fisher Scientific announces license agreement to develop, commercialize deep learning tools for proteomics. News-Medical. Retrieved on October 12, 2024 from https://www.news-medical.net/news/20200528/Thermo-Fisher-Scientific-announces-license-agreement-to-develop-commercialize-deep-learning-tools-for-proteomics.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific announces license agreement to develop, commercialize deep learning tools for proteomics". News-Medical. 12 October 2024. <https://www.news-medical.net/news/20200528/Thermo-Fisher-Scientific-announces-license-agreement-to-develop-commercialize-deep-learning-tools-for-proteomics.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific announces license agreement to develop, commercialize deep learning tools for proteomics". News-Medical. https://www.news-medical.net/news/20200528/Thermo-Fisher-Scientific-announces-license-agreement-to-develop-commercialize-deep-learning-tools-for-proteomics.aspx. (accessed October 12, 2024).

  • Harvard

    Thermo Fisher Scientific Inc.. 2020. Thermo Fisher Scientific announces license agreement to develop, commercialize deep learning tools for proteomics. News-Medical, viewed 12 October 2024, https://www.news-medical.net/news/20200528/Thermo-Fisher-Scientific-announces-license-agreement-to-develop-commercialize-deep-learning-tools-for-proteomics.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Thermo Fisher announces construction of new cGMP plasmid DNA manufacturing facility